Aeglea BioTherapeutics, Inc. (AGLE) financial statements (2021 and earlier)

Company profile

Business Address 805 LAS CIMAS PARKWAY
AUSTIN, TX 78746
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:14672755064
Cash and cash equivalents9019221348
Short-term investments5653523716
Other undisclosed cash, cash equivalents, and short-term investments  (0)0(0)
Receivables   31
Other undisclosed current assets43222
Total current assets:15075775566
Noncurrent Assets
Operating lease, right-of-use asset45
Property, plant and equipment62111
Restricted cash and investments22   
Other noncurrent assets00000
Total noncurrent assets:129111
TOTAL ASSETS:16283785667
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities88432
Accounts payable23100
Accrued liabilities21111
Employee-related liabilities43321
Debt00   
Deferred revenue and credits00
Other undisclosed current liabilities910632
Total current liabilities:16181064
Noncurrent Liabilities
Long-term debt and lease obligation55   
Operating lease, liability55
Liabilities, other than long-term debt00000
Other liabilities00000
Total noncurrent liabilities:55000
Total liabilities:22231064
Stockholders' equity
Stockholders' equity attributable to parent14060675063
Common stock00000
Additional paid in capital416255184123108
Accumulated other comprehensive income (loss)00(0)(0)(0)
Accumulated deficit(276)(195)(117)(73)(45)
Total stockholders' equity:14060675063
TOTAL LIABILITIES AND EQUITY:16283785667

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net55
Gross profit:  455
Operating expenses(81)(80)(49)(33)(27)
Operating loss:(81)(80)(45)(28)(22)
Nonoperating income12100
Investment income, nonoperating12100
Other nonoperating expense(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(81)(78)(44)(27)(22)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(81)(78)(44)(27)(22)
Comprehensive loss:(81)(78)(44)(27)(22)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0)(0)
Comprehensive loss, net of tax, attributable to parent:(81)(78)(44)(27)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: